endocannabinoid system

Endocannabinoid System Dysregulations in Binge Eating Disorder and Obesity

Exploring the endocannabinoid system for intervention innovation in autism

Targeting the Endocannabinoid System for Management of Chemotherapy, HIV and Antiretroviral-Induced Neuropathic Pain

Chemotherapeutic drugs (used for treating cancer), HIV infection and antiretroviral therapy (ART) can independently cause difficult-to-manage painful neuropathy. Paclitaxel, a chemotherapeutic drug, for example is associated with high incidence of peripheral neuropathy, around 71% of the patients of which 27% of these develop neuropathic pain. Use of cannabis or phytocannabinoids has been reported to improve pain measures in patients with neuropathic pain, including painful HIV-associated sensory neuropathy and cancer pain. Phytocannabinoids and endocannabinoids, such as anandamide and 2-arachidonoylglycerol (2-AG), produce their effects via cannabinoid (CB) receptors, which are present both in the periphery and central nervous system. Endocannabinoids are synthesized in an “on demand” fashion and are degraded by various enzymes such as fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MGL). Various studies, including those from our group, suggest that there are changes in gene and protein expression of endocannabinoid molecules during chemotherapy-induced neuropathic pain (CINP), HIV and antiretroviral-induced neuropathic pain. Analysis of endocannabinoid molecule expression in the brain, spinal cord and paw skin using LC-MS/MS show that there is a specific deficiency of the endocannabinoids 2-AG and/or anandamide in the periphery during CINP. Various drugs including endocannabinoids, cannabidiol, inhibitors of FAAH and MGL, CB receptor agonists, desipramine and coadministered indomethacin plus minocycline have been found to either prevent the development and/or attenuate established CINP, HIV and antiretroviral-induced neuropathic pain in a CB receptor-dependent manner. The results available suggest that targeting the endocannabinoid system for prevention and treatment of CINP, HIV-associated neuropathic pain and antiretroviral-induced neuropathic pain is a plausible therapeutic option.

Comparing the role of the endocannabinoid system in the effects of obesogenic diet on memory in females and males

The endocannabinoid system regulates olfactory perception in the anterior piriform cortex

Omega-3 impacts on the long-term impaired endocannabinoid system and behavior after binge drinking during adolescence

Regulation of the endocannabinoid system by serotonergic psychedelics: a lipidomic and behavioral study in rodents

Role of the endocannabinoid system in a genetic model of autism based on FMR1 deletion in rats

Differential modulation of the endocannabinoid system in binge eating disorder and obesity

FENS Forum 2024

Expression of the endocannabinoid system in the visual cortex: Implications for cannabinoid research

FENS Forum 2024

Potential strategy for the therapeutic regulation of the endocannabinoid system with interfering peptides that modulate SGIP1 binding

FENS Forum 2024

Stress-induced potentiation of post-surgical pain and associated alterations in the endocannabinoid system

FENS Forum 2024

Targeting the dysfunctional endocannabinoid system in Gulf War Illness

FENS Forum 2024